{"id":"tubulin","name":"Tubulin (microtubules)","symbol":"TUBB","route":"/targets/tubulin/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20778","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196230","uniprot":"https://www.uniprot.org/uniprotkb/P07437/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P07437","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5444","open-targets":"https://platform.opentargets.org/target/ENSG00000196230","civic":"https://civicdb.org/genes/203068/summary","oncokb":"https://www.oncokb.org/gene/TUBB","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TUBB","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=TUBB","depmap":"https://depmap.org/portal/gene/TUBB?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000196230-TUBB","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/203068","omim":"https://www.omim.org/entry/191130"}],"products":[{"id":"depatuxizumab-mafodotin","name":"Depatuxizumab mafodotin","status":"negative","modality":"EGFR-targeted antibody-drug conjugate (MMAF payload)","route":"/drugs/depatuxizumab-mafodotin/"},{"id":"estramustine","name":"Estramustine","status":"established","modality":"Oral oestradiol and nitrogen mustard conjugate","route":"/drugs/estramustine/"},{"id":"utidelone","name":"Utidelone","status":"approved","modality":"Epothilone analogue, microtubule-stabilising cytotoxic chemotherapy","route":"/drugs/utidelone/"},{"id":"vindesine","name":"Vindesine","status":"established","modality":"Vinca alkaloid, intravenous","route":"/drugs/vindesine/"}],"trials":[{"id":"intellance-1","name":"INTELLANCE-1","nct":"NCT02573324","phase":"3","status":"negative"},{"id":"nct00024167","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","nct":"NCT00024167","phase":"3"},{"id":"nct00004054","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","nct":"NCT00004054","phase":"3","status":"completed"},{"id":"swog-9916","name":"SWOG 9916","nct":"NCT00004001","phase":"3","status":"positive"},{"id":"nct07021261","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","nct":"NCT07021261","phase":"3","status":"planned"},{"id":"nct04221035","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","nct":"NCT04221035","phase":"3","status":"recruiting"},{"id":"nct00055731","name":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","nct":"NCT00055731","phase":"3","status":"completed"},{"id":"nct01117441","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","nct":"NCT01117441","phase":"3","status":"completed"},{"id":"nct03206671","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","nct":"NCT03206671","phase":"3","status":"active"},{"id":"nct06764940","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","nct":"NCT06764940","phase":"2","status":"recruiting"},{"id":"nct06125080","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","nct":"NCT06125080","phase":"2","status":"recruiting"},{"id":"nct06385990","name":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","nct":"NCT06385990","phase":"2","status":"recruiting"},{"id":"nct06683703","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","nct":"NCT06683703","phase":"2","status":"planned"},{"id":"nct05700084","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","nct":"NCT05700084","phase":"1/2","status":"active"}],"pathways":[],"companies":["abbvie","biostar-pharmaceuticals","eli-lilly","pfizer"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}